Steady-state Pharmacokinetics, Cord Blood Concentrations, and Safety of Ritonavir-boosted Fosamprenavir in Pregnancy

Overview

Journal J Acquir Immune Defic Syndr

Specialty Infectious Diseases

Date 2013 Jan 15

PMID 23314414

Citations 6

Authors

Michelle S Cespedes

Delivette Castor

Susan L Ford

Doreen Lee

Yu Lou

Gary E Pakes

Judith A Aberg

Affiliations

Soon will be listed here.

Abstract

Steady-state pharmacokinetics in pregnant women prescribed ritonavir-boosted fosamprenavir (FPV) to prevent HIV transmission were assessed in the second trimester, third trimester, and postpartum. Compared with postpartum, geometric mean amprenavir (APV, FPVs active metabolite) area under the plasma concentration-time curves were 35% lower in the second trimester and 25% lower in the third trimester. Maternal APV concentrations were 9- to 15-fold above the mean APV protein-adjusted 50% inhibitory concentration for wild-type HIV. Median ratio of cord blood/maternal APV levels was 0.27, and all infants were HIV negative. FPV/ritonavir during pregnancy was well tolerated and led to virologic suppression.

Citing Articles

Drug-Drug Interactions with Antiretroviral Drugs in Pregnant Women Living with HIV: Are They Different from Non-Pregnant Individuals?.

Bukkems V, Colbers A, Marzolini C, Molto J, Burger D Clin Pharmacokinet. 2020; 59(10):1217-1236.

PMID: 32696442 PMC: 7550380. DOI: 10.1007/s40262-020-00914-x.

Fosamprenavir with Ritonavir Pharmacokinetics during Pregnancy.

Eke A, Wang J, Amin K, Shapiro D, Stek A, Smith E Antimicrob Agents Chemother. 2020; 64(4).

PMID: 32015036 PMC: 7179299. DOI: 10.1128/AAC.02260-19.

Pregnancy-Associated Changes in Pharmacokinetics: A Systematic Review.

Pariente G, Leibson T, Carls A, Adams-Webber T, Ito S, Koren G PLoS Med. 2016; 13(11):e1002160.

PMID: 27802281 PMC: 5089741. DOI: 10.1371/journal.pmed.1002160.

Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women.

Tran A, Best B, Stek A, Wang J, Capparelli E, Burchett S J Acquir Immune Defic Syndr. 2016; 72(3):289-96.

PMID: 26918544 PMC: 4911231. DOI: 10.1097/QAI.0000000000000968.

Protecting the fetus against HIV infection: a systematic review of placental transfer of antiretrovirals.

McCormack S, Best B Clin Pharmacokinet. 2014; 53(11):989-1004.

PMID: 25223699 PMC: 4214885. DOI: 10.1007/s40262-014-0185-7.

References

Massad L, Springer G, Jacobson L, Watts H, Anastos K, Korn A . Pregnancy rates and predictors of conception, miscarriage and abortion in US women with HIV. AIDS. 2004; 18(2):281-6. DOI: 10.1097/00002030-200401230-00018. View

Aberg J, Kaplan J, Libman H, Emmanuel P, Anderson J, Stone V . Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2009; 49(5):651-81. DOI: 10.1086/605292. View

Yeh R, Rezk N, Kashuba A, Dumond J, Tappouni H, Tien H . Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women. Antimicrob Agents Chemother. 2009; 53(6):2367-74. PMC: 2687255. DOI: 10.1128/AAC.01523-08. View

Pacanowski J, Bollens D, Poirier J, Morand-Joubert L, Castaigne V, Girard P . Efficacy of darunavir despite low plasma trough levels during late pregnancy in an HIV-hepatitis C virus-infected patient. AIDS. 2009; 23(14):1923-4. DOI: 10.1097/QAD.0b013e32832e534b. View

van der Lugt J, Colbers A, Molto J, Hawkins D, van der Ende M, Vogel M . The pharmacokinetics, safety and efficacy of boosted saquinavir tablets in HIV type-1-infected pregnant women. Antivir Ther. 2009; 14(3):443-50. View

Luber A, Condoluci D, Slowinski P, Andrews M, Olson K, Peloquin C . Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers. HIV Med. 2009; 11(3):193-9. DOI: 10.1111/j.1468-1293.2009.00765.x. View

Levey A, Bosch J, Lewis J, Greene T, Rogers N, Roth D . A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999; 130(6):461-70. DOI: 10.7326/0003-4819-130-6-199903160-00002. View

Huang L, Wring S, Woolley J, Brouwer K, Polli J . Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. Drug Metab Dispos. 2001; 29(5):754-60. View

Stek A, Mirochnick M, Capparelli E, Best B, Hu C, Burchett S . Reduced lopinavir exposure during pregnancy. AIDS. 2006; 20(15):1931-9. DOI: 10.1097/01.aids.0000247114.43714.90. View

10.

Read J, Best B, Stek A, Hu C, Capparelli E, Holland D . Pharmacokinetics of new 625 mg nelfinavir formulation during pregnancy and postpartum. HIV Med. 2008; 9(10):875-82. PMC: 2732353. DOI: 10.1111/j.1468-1293.2008.00640.x. View

11.

Correa A, Cragan J, Kucik J, Alverson C, Gilboa S, Balakrishnan R . Reporting birth defects surveillance data 1968-2003. Birth Defects Res A Clin Mol Teratol. 2007; 79(2):65-186. DOI: 10.1002/bdra.20350. View

12.

. Achievements in public health. Reduction in perinatal transmission of HIV infection--United States, 1985-2005. MMWR Morb Mortal Wkly Rep. 2006; 55(21):592-7. View

13.

Villani P, Floridia M, Pirillo M, Cusato M, Tamburrini E, Cavaliere A . Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women. Br J Clin Pharmacol. 2006; 62(3):309-15. PMC: 1885131. DOI: 10.1111/j.1365-2125.2006.02669.x. View

14.

Wire M, Shelton M, Studenberg S . Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clin Pharmacokinet. 2006; 45(2):137-68. DOI: 10.2165/00003088-200645020-00002. View

15.

Best B, Stek A, Mirochnick M, Hu C, Li H, Burchett S . Lopinavir tablet pharmacokinetics with an increased dose during pregnancy. J Acquir Immune Defic Syndr. 2010; 54(4):381-8. PMC: 3265163. DOI: 10.1097/qai.0b013e3181d6c9ed. View

16.

Chen J, Philips K, Kanouse D, Collins R, Miu A . Fertility desires and intentions of HIV-positive men and women. Fam Plann Perspect. 2001; 33(4):144-52, 165. View

17.

Nellen J, Schillevoort I, Wit F, Bergshoeff A, Godfried M, Boer K . Nelfinavir plasma concentrations are low during pregnancy. Clin Infect Dis. 2004; 39(5):736-40. DOI: 10.1086/422719. View

18.

Mirochnick M, Best B, Stek A, Capparelli E, Hu C, Burchett S . Atazanavir pharmacokinetics with and without tenofovir during pregnancy. J Acquir Immune Defic Syndr. 2011; 56(5):412-9. PMC: 3125419. DOI: 10.1097/QAI.0b013e31820fd093. View

19.

Martorell C, Theroux E, Bermudez A, Garb J, Kronschnabel D, Oie K . Safety and efficacy of fosamprenavir in human immunodeficiency virus-infected pregnant women. Pediatr Infect Dis J. 2010; 29(10):985. DOI: 10.1097/INF.0b013e3181ef0336. View

20.

Acosta E, Bardeguez A, Zorrilla C, Van Dyke R, Hughes M, Huang S . Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother. 2004; 48(2):430-6. PMC: 321538. DOI: 10.1128/AAC.48.2.430-436.2004. View